Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.

Liraglutide pre-filled pen, a GLP-1 peptide drug that will be marketed under the brand name Milmiga®, is a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes. Victoza achieved sales exceeding €27 million in Scandinavia, as reported by DLMI. 

“The successful approval of Liraglutide highlights our capability to offer a diverse and comprehensive portfolio, encompassing both complex peptide injectables and small molecule oral treatments.” says Mr Lars Minor CEO of Newbury
Datum 2024-06-20, kl 13:00
Källa MFN
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.